264 related articles for article (PubMed ID: 10889378)
21. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous beam geometry and intensity map optimization in intensity-modulated radiation therapy.
Lee EK; Fox T; Crocker I
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):301-20. PubMed ID: 16289912
[TBL] [Abstract][Full Text] [Related]
23. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
[TBL] [Abstract][Full Text] [Related]
24. Rapid Arc, helical tomotherapy, sliding window intensity modulated radiotherapy and three dimensional conformal radiation for localized prostate cancer: a dosimetric comparison.
Kinhikar RA; Pawar AB; Mahantshetty U; Murthy V; Dheshpande DD; Shrivastava SK
J Cancer Res Ther; 2014; 10(3):575-82. PubMed ID: 25313742
[TBL] [Abstract][Full Text] [Related]
25. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
Ryu JK; Winter K; Michalski JM; Purdy JA; Markoe AM; Earle JD; Perez CA; Roach M; Sandler HM; Pollack A; Cox JD
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1036-46. PubMed ID: 12419429
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition.
Sachpazidis I; Mavroidis P; Zamboglou C; Klein CM; Grosu AL; Baltas D
Radiat Oncol; 2020 Oct; 15(1):242. PubMed ID: 33081804
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.
Kattan MW; Zelefsky MJ; Kupelian PA; Cho D; Scardino PT; Fuks Z; Leibel SA
J Clin Oncol; 2003 Dec; 21(24):4568-71. PubMed ID: 14673043
[TBL] [Abstract][Full Text] [Related]
28. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
Zelefsky MJ; Leibel SA; Gaudin PB; Kutcher GJ; Fleshner NE; Venkatramen ES; Reuter VE; Fair WR; Ling CC; Fuks Z
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):491-500. PubMed ID: 9635694
[TBL] [Abstract][Full Text] [Related]
29. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).
Kupelian PA; Buchsbaum JC; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):621-5. PubMed ID: 11395228
[TBL] [Abstract][Full Text] [Related]
30. Importance of protocol target definition on the ability to spare normal tissue: an IMRT and 3D-CRT planning comparison for intraorbital tumors.
Hein PA; Gladstone DJ; Bellerive MR; Hug EB
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1540-8. PubMed ID: 16029816
[TBL] [Abstract][Full Text] [Related]
31. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
32. Postoperative intensity modulated radiation therapy in high risk prostate cancer: a dosimetric comparison.
Digesú C; Cilla S; De Gaetano A; Massaccesi M; Macchia G; Ippolito E; Deodato F; Panunzi S; Iapalucci C; Mattiucci GC; D'Angelo E; Padula GD; Valentini V; Cellini N; Piermattei A; Morganti AG
Med Dosim; 2011; 36(3):231-9. PubMed ID: 20541394
[TBL] [Abstract][Full Text] [Related]
33. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
34. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation.
Ahmad S; Vogds BJ; McKenna F; Vlachaki MT
J Xray Sci Technol; 2009; 17(4):347-54. PubMed ID: 19923690
[TBL] [Abstract][Full Text] [Related]
35. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
36. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
37. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
[TBL] [Abstract][Full Text] [Related]
38. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
39. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
40. A dynamic compensation strategy to correct patient-positioning errors in conformal prostate radiotherapy.
Lauve AD; Siebers JV; Crimaldi AJ; Hagan MP; Kealla PJ
Med Phys; 2006 Jun; 33(6):1879-87. PubMed ID: 16872095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
